drugset / Trial / NCT01440920
A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability of OCV-501 in patients with acute myeloid leukemia (AML) who achieved complete remission after induction regimen and who completed a standard consolidation therapy.
Timeline
- Start
- 2011-09
- Primary completion
- 2013-03
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OCV-501 | Unknown | 0.3 mg | Subcutaneous |
| Subject | OCV-501 | Unknown | 1 mg | Subcutaneous |
| Subject | OCV-501 | Unknown | 3 mg | Subcutaneous |